# Vital Farms, Inc.: financial statements, quarterly

VITL · Nasdaq · CIK 1579733 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 27

Pages: [Overview](/companies/vitl.md) · [Financials](/companies/vitl/financials.md) · [Filings](/companies/vitl/filings.md) · [Insiders](/companies/vitl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vitl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-24) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [110](/filings/0000950170-24-122803.md) | [136 d](/filings/0001193125-26-073423.md) | [148](/filings/0000950170-25-066392.md) | [147](/filings/0000950170-25-104564.md) | [145](/filings/0001193125-25-263590.md) | [166 d](/filings/0001193125-26-073423.md) | [162](/filings/0001193125-26-210356.md) | [185](/filings/0001193125-26-336753.md) | [199](/filings/0001193125-25-263590.md) | [214 d](/filings/0001193125-26-073423.md) | [187](/filings/0001193125-26-210356.md) | [166](/filings/0001193125-26-336753.md) |
| Cost of revenue | $m | [73.8](/filings/0000950170-24-122803.md) | [90.6 d](/filings/0001193125-26-073423.md) | [89.0](/filings/0000950170-25-066392.md) | [89.7](/filings/0000950170-25-104564.md) | [91.5](/filings/0001193125-25-263590.md) | [106 d](/filings/0001193125-26-073423.md) | [99.7](/filings/0001193125-26-210356.md) | [113](/filings/0001193125-26-336753.md) | [124](/filings/0001193125-25-263590.md) | [137 d](/filings/0001193125-26-073423.md) | [134](/filings/0001193125-26-210356.md) | [155](/filings/0001193125-26-336753.md) |
| Gross profit | $m | [36.7](/filings/0000950170-24-122803.md) | [45.2 d](/filings/0001193125-26-073423.md) | [58.9](/filings/0000950170-25-066392.md) | [57.7](/filings/0000950170-25-104564.md) | [53.5](/filings/0001193125-25-263590.md) | [59.9 d](/filings/0001193125-26-073423.md) | [62.5](/filings/0001193125-26-210356.md) | [71.8](/filings/0001193125-26-336753.md) | [75.0](/filings/0001193125-25-263590.md) | [76.4 d](/filings/0001193125-26-073423.md) | [53.0](/filings/0001193125-26-210356.md) | [10.9](/filings/0001193125-26-336753.md) |
| Selling, general and administrative | $m | [25.1](/filings/0000950170-24-122803.md) | [28.8 d](/filings/0001193125-26-073423.md) | [27.1](/filings/0000950170-25-066392.md) | [33.3](/filings/0000950170-25-104564.md) | [36.1](/filings/0001193125-25-263590.md) | [37.4 d](/filings/0001193125-26-073423.md) | [31.9](/filings/0001193125-26-210356.md) | [39.0](/filings/0001193125-26-336753.md) | [44.4](/filings/0001193125-25-263590.md) | [44.1 d](/filings/0001193125-26-073423.md) | [44.4](/filings/0001193125-26-210356.md) | [40.4](/filings/0001193125-26-336753.md) |
| Operating income | $m | [5.2](/filings/0000950170-24-122803.md) | [9.1 d](/filings/0001193125-26-073423.md) | [24.2](/filings/0000950170-25-066392.md) | [17.1](/filings/0000950170-25-104564.md) | [9.2](/filings/0001193125-25-263590.md) | [13.0 d](/filings/0001193125-26-073423.md) | [21.8](/filings/0001193125-26-210356.md) | [23.8](/filings/0001193125-26-336753.md) | [21.4](/filings/0001193125-25-263590.md) | [21.4 d](/filings/0001193125-26-073423.md) | [(2.3)](/filings/0001193125-26-210356.md) | [(40.1)](/filings/0001193125-26-336753.md) |
| Interest expense | $m | [0.2](/filings/0000950170-23-057826.md) | [0.3 d](/filings/0000950170-24-027602.md) | [0.3](/filings/0000950170-24-056285.md) | [0.3](/filings/0000950170-24-093329.md) | [0.3](/filings/0001193125-25-263590.md) | [0.2 d](/filings/0001193125-26-073423.md) | [0.2](/filings/0001193125-26-210356.md) | [0.2](/filings/0001193125-26-336753.md) | [0.2](/filings/0001193125-25-263590.md) | [0.2 d](/filings/0001193125-26-073423.md) | [0.2](/filings/0001193125-26-210356.md) | [0.4](/filings/0001193125-26-336753.md) |
| Income tax | $m | [0.5](/filings/0000950170-24-122803.md) | [2.4 d](/filings/0001193125-26-073423.md) | [5.7](/filings/0000950170-25-066392.md) | [1.8](/filings/0000950170-25-104564.md) | [2.9](/filings/0001193125-25-263590.md) | [3.7 d](/filings/0001193125-26-073423.md) | [5.4](/filings/0001193125-26-210356.md) | [7.9](/filings/0001193125-26-336753.md) | [5.6](/filings/0001193125-25-263590.md) | [6.1 d](/filings/0001193125-26-073423.md) | [(0.3)](/filings/0001193125-26-210356.md) | [(9.7)](/filings/0001193125-26-336753.md) |
| Net income | $m | [4.5](/filings/0000950170-24-122803.md) | [7.2 d](/filings/0001193125-26-073423.md) | [19.0](/filings/0001193125-25-263590.md) | [16.3](/filings/0001193125-25-263590.md) | [7.4](/filings/0001193125-25-263590.md) | [10.6 d](/filings/0001193125-26-073423.md) | [16.9](/filings/0001193125-26-336753.md) | [16.6](/filings/0001193125-26-336753.md) | [16.4](/filings/0001193125-25-263590.md) | [16.3 d](/filings/0001193125-26-073423.md) | [(1.5)](/filings/0001193125-26-336753.md) | [(31.1)](/filings/0001193125-26-336753.md) |
| Diluted EPS | $ per share | [0.10](/filings/0000950170-24-122803.md) | not reported | [0.43](/filings/0000950170-25-066392.md) | [0.36](/filings/0000950170-25-104564.md) | [0.16](/filings/0001193125-25-263590.md) | not reported | [0.37](/filings/0001193125-26-210356.md) | [0.36](/filings/0001193125-26-336753.md) | [0.36](/filings/0001193125-25-263590.md) | not reported | [(0.03)](/filings/0001193125-26-210356.md) | [(0.72)](/filings/0001193125-26-336753.md) |
| Basic EPS | $ per share | [0.11](/filings/0000950170-24-122803.md) | not reported | [0.46](/filings/0000950170-25-066392.md) | [0.38](/filings/0000950170-25-104564.md) | [0.17](/filings/0001193125-25-263590.md) | not reported | [0.38](/filings/0001193125-26-210356.md) | [0.37](/filings/0001193125-26-336753.md) | [0.37](/filings/0001193125-25-263590.md) | not reported | [(0.03)](/filings/0001193125-26-210356.md) | [(0.72)](/filings/0001193125-26-336753.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-24) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | FY2025 (2025-12-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [56.8](/filings/0000950170-23-057826.md) | [84.1](/filings/0000950170-25-028365.md) | [114](/filings/0000950170-24-056285.md) | [133](/filings/0000950170-24-093329.md) | [150](/filings/0000950170-24-122803.md) | [151](/filings/0001193125-26-073423.md) | [156](/filings/0000950170-25-066392.md) | [108](/filings/0000950170-25-104564.md) | [93.8](/filings/0001193125-25-263590.md) | [48.8](/filings/0001193125-26-336753.md) | [36.6](/filings/0001193125-26-210356.md) | [21.2](/filings/0001193125-26-336753.md) |
| Current assets | $m | [177](/filings/0000950170-23-057826.md) | [196](/filings/0000950170-25-028365.md) | [218](/filings/0000950170-24-056285.md) | [234](/filings/0000950170-24-093329.md) | [252](/filings/0000950170-24-122803.md) | [246](/filings/0001193125-26-073423.md) | [260](/filings/0000950170-25-066392.md) | [275](/filings/0000950170-25-104564.md) | [272](/filings/0001193125-25-263590.md) | [263](/filings/0001193125-26-336753.md) | [209](/filings/0001193125-26-210356.md) | [163](/filings/0001193125-26-336753.md) |
| Total assets | $m | [250](/filings/0000950170-23-057826.md) | [275](/filings/0000950170-25-028365.md) | [300](/filings/0000950170-24-056285.md) | [320](/filings/0000950170-24-093329.md) | [345](/filings/0000950170-24-122803.md) | [359](/filings/0001193125-26-073423.md) | [377](/filings/0000950170-25-066392.md) | [431](/filings/0000950170-25-104564.md) | [482](/filings/0001193125-25-263590.md) | [519](/filings/0001193125-26-336753.md) | [493](/filings/0001193125-26-210356.md) | [502](/filings/0001193125-26-336753.md) |
| Current liabilities | $m | [53.0](/filings/0000950170-23-057826.md) | [65.2](/filings/0000950170-25-028365.md) | [70.4](/filings/0000950170-24-056285.md) | [67.0](/filings/0000950170-24-093329.md) | [77.7](/filings/0000950170-24-122803.md) | [78.5](/filings/0001193125-26-073423.md) | [77.5](/filings/0000950170-25-066392.md) | [111](/filings/0000950170-25-104564.md) | [103](/filings/0001193125-25-263590.md) | [122](/filings/0001193125-26-336753.md) | [118](/filings/0001193125-26-210356.md) | [148](/filings/0001193125-26-336753.md) |
| Total liabilities | $m | [67.2](/filings/0000950170-23-057826.md) | [82.5](/filings/0000950170-25-028365.md) | [86.9](/filings/0000950170-24-056285.md) | [82.1](/filings/0000950170-24-093329.md) | [91.3](/filings/0000950170-24-122803.md) | [90.0](/filings/0001193125-26-073423.md) | [88.0](/filings/0000950170-25-066392.md) | [121](/filings/0000950170-25-104564.md) | [150](/filings/0001193125-25-263590.md) | [167](/filings/0001193125-26-336753.md) | [162](/filings/0001193125-26-210356.md) | [218](/filings/0001193125-26-336753.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-336753.md) | not reported | [30.0](/filings/0001193125-26-336753.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [183](/filings/0000950170-24-122803.md) | [193](/filings/0001193125-26-073423.md) | [213](/filings/0001193125-25-263590.md) | [238](/filings/0001193125-25-263590.md) | [253](/filings/0001193125-25-263590.md) | [269](/filings/0001193125-26-336753.md) | [289](/filings/0001193125-26-336753.md) | [310](/filings/0001193125-26-336753.md) | [331](/filings/0001193125-25-263590.md) | [351](/filings/0001193125-26-336753.md) | [331](/filings/0001193125-26-336753.md) | [284](/filings/0001193125-26-336753.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-24) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [8.3 d](/filings/0000950170-24-122803.md) | [23.7 d](/filings/0001193125-26-073423.md) | [23.9](/filings/0000950170-25-066392.md) | [16.1 d](/filings/0000950170-25-104564.md) | [10.0 d](/filings/0001193125-25-263590.md) | [14.8 d](/filings/0001193125-26-073423.md) | [5.3](/filings/0001193125-26-210356.md) | [(0.8) d](/filings/0001193125-26-336753.md) | [23.4 d](/filings/0001193125-25-263590.md) | [5.8 d](/filings/0001193125-26-073423.md) | [(18.6)](/filings/0001193125-26-210356.md) | [(27.4) d](/filings/0001193125-26-336753.md) |
| Capital expenditure | $m | [4.8 d](/filings/0000950170-24-122803.md) | [2.4 d](/filings/0001193125-26-073423.md) | [1.3](/filings/0000950170-25-066392.md) | [5.6 d](/filings/0000950170-25-104564.md) | [3.6 d](/filings/0001193125-25-263590.md) | [18.2 d](/filings/0001193125-26-073423.md) | [3.1](/filings/0001193125-26-210356.md) | [6.9 d](/filings/0001193125-26-336753.md) | [34.0 d](/filings/0001193125-25-263590.md) | [37.9 d](/filings/0001193125-26-073423.md) | [20.8](/filings/0001193125-26-210356.md) | [16.7 d](/filings/0001193125-26-336753.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-210356.md) | [0.0 d](/filings/0001193125-26-336753.md) | not reported | not reported | [20.0](/filings/0001193125-26-210356.md) | [15.2 d](/filings/0001193125-26-336753.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-25) | Q1 FY2023 (2023-03-26) | Q2 FY2023 (2023-06-25) | Q3 FY2023 (2023-09-24) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.9](/filings/0000950170-23-057826.md) | [43.4](/filings/0000950170-24-056285.md) | [43.3](/filings/0000950170-24-093329.md) | [43.1](/filings/0000950170-24-122803.md) | [43.8](/filings/0000950170-25-066392.md) | [45.2](/filings/0000950170-25-104564.md) | [45.5](/filings/0001193125-25-263590.md) | [45.8](/filings/0001193125-26-210356.md) | [45.8](/filings/0001193125-26-336753.md) | [46.2](/filings/0001193125-25-263590.md) | [44.6](/filings/0001193125-26-210356.md) | [42.9](/filings/0001193125-26-336753.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,931,522 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336753.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.